Economic effects of ROTEM®- based bleeding control
It was shown that besides better patient care, effective cost savings are possible by following ROTEM® guided therapy.
The economic and the clinical effectiveness of ROTEM® diagnostic was demonstrated in clinical studies and health technology assessments. This resulted in the following recommendations: ESA guideline, ASA guideline, NICE recommendation, PPH guidance of the SSC ISTH and European Trauma Guideline.
Proven cost saving potential
The use of ROTEM® as a diagnostic tool in perioperative bleeding management is implemented in numerous guidelines:
- Liver transplant
The cost saving potential of ROTEM® guided therapy has repeatedly been proven. It significantly reduces clinical complications and the use of unnecessary blood product. The reduced complication rate could amount to additional cost savings by reducing intensive care unit and hospital stay time!
Bleeding leads to massive costs
The cost of blood products account for a major part of hospital expenses and annually rise by at least 10%. Due to the growing number of surgical interventions, these costs are expected to rise even further. Donor numbers are continuously declining, the population is aging and the need for blood products may not be met. Expenses for storage and the testing and administration of blood products are often underestimated in hospital budgets, contributing to the hospital cost burden.
Improved patient outcome
Substantial blood savings of up to 50% can be made through individualised bleeding management and comprehensive diagnostic results. In particular, thromboelastometry with ROTEM® has been proven to decrease transfusion volumes and shorten hospital stay durations following elective procedures, such as liver transplantation and cardiac surgery. Similar cost-savings are being investigated in other application fields such as trauma care (polytrauma, brain injury etc.), obstetrics (e.g. post-partum haemorrhage) or orthopaedics.